New pill aims to tame seizures in rare brain disorders
Disease control
Not yet recruiting
This early-stage trial tests an oral drug called SVG103 (Paxalisib) in 15 adults with rare brain conditions (FCD-II, TSC, or HME) that cause seizures. The main goal is to check safety and side effects, while also seeing if it reduces seizure frequency. Participants take the drug …
Phase: PHASE1, PHASE2 • Sponsor: Sovargen • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC